| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PFE | Common Stock | Options Exercise | $18.2M | +583K | +167.04% | $31.31 | 932K | Feb 27, 2025 | Direct | F1 |
| transaction | PFE | Common Stock | Tax liability | -$478K | -18.3K | -1.96% | $26.10 | 913K | Feb 27, 2025 | Direct | F2 |
| transaction | PFE | Common Stock | Tax liability | -$14.2M | -546K | -59.76% | $26.06 | 368K | Feb 27, 2025 | Direct | F3, F4 |
| holding | PFE | Common Stock | 5.36K | Feb 27, 2025 | By Rule 16b-3 Plan |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PFE | Stock Appreciation Rights | Options Exercise | $0 | -583K | -100% | $0.00 | 0 | Feb 27, 2025 | Common Stock | 583K | $31.31 | Direct |
| Id | Content |
|---|---|
| F1 | The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). |
| F2 | The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. |
| F3 | The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). |
| F4 | Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. |